Lipoprotein(a) Awareness Day 2023
The Family Heart Foundation established Lipoprotein(a) Awareness Day to raise awareness worldwide of elevated Lipoprotein(a), also known as Lp(a). On March 24, we will use the power
The Family Heart Foundation established Lipoprotein(a) Awareness Day to raise awareness worldwide of elevated Lipoprotein(a), also known as Lp(a). On March 24, we will use the power
Research published on Feb. 20, 2023, by Rafiqul Islam, PhD, and colleagues from Queensland University of Technology may have uncovered a concrete link between blood
In honor of World Sleep Day 2023, we sat down with Cardiometabolic Health Congress (CMHC) faculty member Lee A. Surkin, MD, founder of the American
Sleep Awareness Week® is observed from March 12-18, 2023. This year, the National Sleep Foundation (NSF) is celebrating the 25th anniversary of this annual call
Researchers from Cleveland Clinic looking for new links to cardiovascular disease found that high levels of erythritol in the blood contributed to a higher risk
In an era when health care and pharmaceutical prices continue to trend upwards, Eli Lilly made a historic announcement on Wednesday, March 1, 2023, stating
Were you one of the forward-thinking providers in attendance for the Cardiometabolic Health Congress (CMHC) webinar, Accelerating Diversity, Equity, and Inclusion in Cardiometabolic Health? In
In recognition of Black History and Women’s History Months in February and March 2023, Cardiometabolic Health Congress (CMHC) hosted a one-hour virtual experience to address
In recognition of Black History and Women’s History Months in February and March 2023, Cardiometabolic Health Congress (CMHC) hosted a one-hour virtual experience to address
In recognition of Black History and Women’s History Months in February and March 2023, Cardiometabolic Health Congress (CMHC) hosted a one-hour virtual experience to address
There have been myriad studies investigating the possible connections between cardiometabolic conditions and neurodegeneration. Considering heart disease and neurological disorders are the leading causes of
Eli LIlly’s tirzepatide (Monjaro) could become the most popular weight-loss drug ever if approved, but there are significant concerns about if it will be affordable
On Jan. 12, 2023, Novo Nordisk announced the US Food and Drug Administration (FDA) approved a label update to permit first-line use of semaglutide (Rybelsus)
In early 2023, the American Academy of Pediatrics (AAP) released its first comprehensive guideline in 15 years addressing how providers should approach the care and
On Jan. 13th, 2023, Cardiometabolic Health Congress (CMHC) faculty member Keith C. Ferdinand, MD, was awarded the Living Legends Award from the Southern University at
Legislation signed into law by President Biden ends the requirement that potential drugs must be tested in animals prior to receiving U.S. Food and Drug
An article published in eBioMedicine – part of The Lancet Discovery Science – suggests that individuals with high serum sodium tend to be biologically older,
CinCor’s experimental therapy baxdrostat is in development to treat conditions including high blood pressure and chronic kidney disease by blocking the production of aldosterone, an
Cardiometabolic Health Congress (CMHC) congratulates the winner of the #IAmCardiometabolicHealth contest, Shannon Christen, RD, CDCES, CCHP! In Nov. 2022, CMHC launched a social media contest
In the first big pharmaceutical development of 2023, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for
Recent findings from a University of Calgary study show that individuals who recently received an influenza vaccination had a 22.5% lower risk of stroke compared
On Jan. 1, 2023, Dr. Fatima Cody Stanford sat down with Lesley Stahl of CBS News and 60 Minutes to discuss provider bias and roadblocks
The experts at Cardiometabolic Health Congress (CMHC) have selected the TOP 10 developments, approvals, news, and findings from 2022 that impact the field of cardiorenal
Recent findings from FIDELITY-HF support the use of finerenone and highlight the importance of routine screening for renal function in primary care to identify kidney
On Wednesday, Dec. 7, 2022, many providers tuned into the virtual webinar from Cardiometabolic Health Congress (CMHC) and Carl J. Streed, Jr., MD, MPH. In
Esperion has announced a trial demonstrated a significant risk reduction in MACE-4 in patients treated with Nexletol compared to a placebo.
The FDA has approved Eli Lilly’s insulin glargine-aglr, sold under the brand name Rezvoglar.
Researchers have found consuming certain forms of honey may improve glycemic control and lipid levels when part of a healthy dietary pattern.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Cardiometabolic Health Congress
1801 N Military Trail, Ste 200
Boca Raton, FL, 33431
Copyright © 2023, Cardiometabolic Health Congress. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
